THE APEX TIMES
The company said new Phase 4 data showed statistically significant improvements on MRI-confirmed spinal outcomes in a study of its psoriasis drug TREMFYA for psoriatic arthritis affecting the spine.
Johnson & Johnson said it has posted new Phase 4 results from its STAR trial evaluating TREMFYA in people with psoriatic arthritis that includes axial involvement, meaning disease activity involving the spine. The company framed the findings as a “win” in the study’s MRI-confirmed spinal endpoints and said the improvements were statistically significant.
Phase 4 trials are typically conducted after a treatment is already approved, with the goal of confirming safety and efficacy in broader or more specific patient groups, testing additional dosing approaches, or evaluating clinical outcomes using measures that can include imaging. In the STAR study, the MRI-confirmed spinal outcomes were described by the company as showing statistically significant improvement versus the comparator used in the trial.
The update was published through Yahoo Finance, which summarized the Phase 4 results as showing improvements in MRI-confirmed spinal measures in psoriatic arthritis patients with axial involvement. The company’s headline claim centered on imaging-confirmed change in the spine, a clinically important area because axial disease can be harder to assess using symptoms alone.
While Johnson & Johnson highlighted the statistical significance of the MRI-confirmed spinal improvements, the information made available in the market-news report does not provide additional granular details such as the specific magnitude of change, the duration over which MRI effects were measured, the size of the study population, or the exact statistical thresholds. It also does not spell out safety findings, adverse event rates, or discontinuation rates in the summary presented.
TREMFYA (guselkumab) is part of Johnson & Johnson’s immunology portfolio, targeting inflammatory pathways associated with immune-mediated conditions. In psoriatic arthritis, including axial disease, the therapeutic goal is not only to reduce symptoms but also to slow inflammatory changes that can be detected by imaging. Johnson & Johnson’s emphasis on MRI endpoints suggests the company is seeking to strengthen the evidence base for disease-modifying effects in the spine rather than relying solely on patient-reported measures.
For the broader market, Phase 4 wins in imaging-focused outcomes can matter because they may support future regulatory and payer discussions, particularly in segments where imaging is used to quantify treatment response. In psoriatic arthritis with axial involvement, companies typically compete on whether they can demonstrate durable improvements that map to both clinical symptoms and radiographic or MRI activity. The market impact of the announcement will depend on how regulators and clinicians interpret the missing specifics, including effect sizes and consistency across subgroups.
What remains unclear from the available summary is the full set of trial endpoints, whether the MRI spinal improvements translated into improvements across peripheral arthritis measures, and how the company characterized safety over the study period. Until Johnson & Johnson or its investigators release additional materials that include results tables, secondary endpoint outcomes, and safety details, investors and clinicians may not be able to fully benchmark the findings against other therapies targeting similar pathways.
Microsoft says it is partnering with Danaher to apply artificial intelligence and cloud infrastructure to scientific laboratories, aiming to improve how lab instruments and workflows are automated and managed.
A steep drop in Anthropic’s trading debut has highlighted how much leverage Amazon and Alphabet have through equity exposure, even as an outside analyst argued Anthropic is also accelerating demand across major cloud platforms.
A market commentary piece looking out to 2028 suggests both semiconductor names could rise, but argues NVIDIA may have the edge. The companies themselves did not disclose any new, time-bound price targets in the commentary.
The update pegs a revised valuation roughly 22% above the stock’s level at the time of the post, with the author pointing to a dominant contributor to the estimate.
President Trump said he would cap credit card interest rates at 10%, a step that would run counter to a reported industry median card rate near 22.2%. The proposal could pressure earnings models for major lenders such as JPMorgan Chase and Citigroup, depending on how the cap is designed and enforced.
Walmart’s warehouse club is changing how membership is packaged, a move that could strengthen retention for Sam’s Club customers without necessarily pressuring Costco’s model, according to a report by Yahoo Finance.
Tracking 13F reports for the quarter ended Sept. 30, 20 large funds reported buying Mastercard while 18 reported selling, a split that highlights how institutional positioning can diverge even when the same stock is in the spotlight.
A Yahoo Finance report says a major customer has reduced planned purchases of Broadcom AI accelerators used in Google’s data centers. Broadcom and Google have not, in the report, provided shipment detail or a formal explanation.
The world’s largest retailer is preparing for a rare holiday policy shift, with store closures scheduled to reduce late-season operating hours for millions of shoppers.
Microsoft CEO Satya Nadella said “selling to one or two customers is not a business,” arguing that AI capacity providers should build their own resources first and rent last. The remark lands as investors focus on companies that monetize cloud and chip demand through concentrated customer relationships.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...